Silvia Surini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silvia Surini has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Christina Avanti
Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia
4 shared publications - Kurnia Sari Setio Putri
Faculty of Pharmacy, Universitas Indonesia, Depok 16424, Indonesia
3 shared publications - Anton Bahtiar
Disease-Related Biomarker and Prospective Therapy Cluster, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok, Depok 16424, West Java, Indonesia
2 shared publications Astried Leonyza
Laboratory of Pharmaceutics and Pharmaceutical Technology Development, Faculty of Pharmacy, Universitas Indonesia, Depok, West Java, 16424, Indonesia
2 shared publicationsE. Anwar
2 shared publications- Endang Wahyu Fitriani
Faculty of Pharmacy
2 shared publications
Latest Publications
- Open Access
- 1 May 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (3) , 774-786
Utilization of glucomannan-xanthan gum-carrageenan based co-processed excipients in the development of nutraceutical pomegranate (Punica granatum L.) peel extract jelly
Context: The expanding product market presents an opportunity for the creation of innovative nutraceuticals incorporating pomegranate (Punica granatum L.) peel extract (PPE) in attractive dosage forms. In this context, novel dosage forms such as jelly are widely accepted due to their appealing qualities. However, achieving a desirable chewy texture throughout jelly production necessitates the use of a gelling agent with high gel strength, prompting the exploration of superior excipients. This study focuses on the development and application of new excipient combinations, namely carrageenan, xanthan gum, and glucomannan, as gelling agents in pomegranate peel extract jelly (PPEJ). Aims: To develop new co-processed excipients consisting of glucomannan, xanthan gum, and carrageenan and assess the suitability of developing PPEJ as a nutraceutical product. Methods: A total of eight formulae of co-processed excipients were obtained through the co-drying process and were physically, chemically, and functionally characterized. The developed excipients were used as gelling agents in nutraceutical PPEJ and subjected to physical and hedonic evaluation. Results: Co-processing improved excipient's functional qualities, while negligible chemical interactions were verified by FT-IR, DSC, and XRD analyses. Furthermore, GLU-XAG-CAR-7 had the highest gel strength value (1659.25 ± 70.17 g) and was selected for jelly formulation. Texture and hedonic evaluations showed that PPEJ-C had the highest GLU-XAG-CAR-7 concentration formula and produced the best jelly. Conclusions: The new co-processed excipients show remarkable potential to be used as a gelling agent in the formulation of PPEJ.
- 1 May 2025
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 13 (3) , 774-786
Open AccessUtilization of glucomannan-xanthan gum-carrageenan based co-processed excipients in the development of nutraceutical pomegranate (Punica granatum L.) peel extract jelly
Context: The expanding product market presents an opportunity for the creation of innovative nutraceuticals incorporating pomegranate (Punica granatum L.) peel extract (PPE) in attractive dosage forms. In this context, novel dosage forms such as jelly are widely accepted due to their appealing qualities. However, achieving a desirable chewy texture throughout jelly production necessitates the use of a gelling agent with high gel strength, prompting the exploration of superior excipients. This study focuses on the development and application of new excipient combinations, namely carrageenan, xanthan gum, and glucomannan, as gelling agents in pomegranate peel extract jelly (PPEJ). Aims: To develop new co-processed excipients consisting of glucomannan, xanthan gum, and carrageenan and assess the suitability of developing PPEJ as a nutraceutical product. Methods: A total of eight formulae of co-processed excipients were obtained through the co-drying process and were physically, chemically, and functionally characterized. The developed excipients were used as gelling agents in nutraceutical PPEJ and subjected to physical and hedonic evaluation. Results: Co-processing improved excipient's functional qualities, while negligible chemical interactions were verified by FT-IR, DSC, and XRD analyses. Furthermore, GLU-XAG-CAR-7 had the highest gel strength value (1659.25 ± 70.17 g) and was selected for jelly formulation. Texture and hedonic evaluations showed that PPEJ-C had the highest GLU-XAG-CAR-7 concentration formula and produced the best jelly. Conclusions: The new co-processed excipients show remarkable potential to be used as a gelling agent in the formulation of PPEJ.
- Open Access
- 28 April 2025
- Published by Universitas Pancasila in JURNAL ILMU KEFARMASIAN INDONESIA
- Vol. 23 (1) , 123
Natural deep eutectic solvents (NaDES) improves extraction and antioxidant activity of stem bark of Garcinia cowa Roxb.
Garcinia cowa Roxb. ex DC. is a plant belonging to the Clusiaceae family, and commonly dicovered in Southeast and South Asia. This study aimed to assess the efficiency of eight natural deep eutectic solvents (NaDES) in extracting total xanthones and phenolic compounds from the stem bark using ultrasound-assisted extraction as there is limited research on the use of NaDES in this plant extraction process. The study also examined their antioxidant properties. The NaDES were synthesized with choline chloride and betaine as hydrogen-bond acceptors, accompanied by various acids, alcohols, and glucose as hydrogen-bond donors. In comparison, ethanol was used as standard solvent. The NaDES exhibited higher densities than water, ranging from 1.059 to 1.244 g/cm³, with density increasing according to the number of hydroxyl groups present in the constituents. The total phenolic content (TPC) varied from 22.82 to 28.73 mg GAE/g extract, with NaDES1 (a combination of choline chloride, 1,2-propanediol, and water in a ratio of 1:3:1) showing the highest TPC at 28.73±0.18 mg GAE/g extract. It also exhibited significant antioxidant activities, as demonstrated by DPPH (28.98±0.03 µg/mL) and FRAP assays (43.66±1.51 mmol trolox/g dw). A significant negative correlation was observed between total xanthone, total phenolic content, and IC50 values. These findings suggest that NaDES, particularly NaDES1, have considerable advantages in extracting phenolic compounds and xanthones from G. cowa stem bark, resulting in enhanced antioxidant properties.This highlights the potential of NaDES as eco-friendly and effective solvents for the extraction of bioactive compounds from plant materials.
- 28 April 2025
- Published by Universitas Pancasila in JURNAL ILMU KEFARMASIAN INDONESIA
- Vol. 23 (1) , 123
Open AccessNatural deep eutectic solvents (NaDES) improves extraction and antioxidant activity of stem bark of Garcinia cowa Roxb.
Garcinia cowa Roxb. ex DC. is a plant belonging to the Clusiaceae family, and commonly dicovered in Southeast and South Asia. This study aimed to assess the efficiency of eight natural deep eutectic solvents (NaDES) in extracting total xanthones and phenolic compounds from the stem bark using ultrasound-assisted extraction as there is limited research on the use of NaDES in this plant extraction process. The study also examined their antioxidant properties. The NaDES were synthesized with choline chloride and betaine as hydrogen-bond acceptors, accompanied by various acids, alcohols, and glucose as hydrogen-bond donors. In comparison, ethanol was used as standard solvent. The NaDES exhibited higher densities than water, ranging from 1.059 to 1.244 g/cm³, with density increasing according to the number of hydroxyl groups present in the constituents. The total phenolic content (TPC) varied from 22.82 to 28.73 mg GAE/g extract, with NaDES1 (a combination of choline chloride, 1,2-propanediol, and water in a ratio of 1:3:1) showing the highest TPC at 28.73±0.18 mg GAE/g extract. It also exhibited significant antioxidant activities, as demonstrated by DPPH (28.98±0.03 µg/mL) and FRAP assays (43.66±1.51 mmol trolox/g dw). A significant negative correlation was observed between total xanthone, total phenolic content, and IC50 values. These findings suggest that NaDES, particularly NaDES1, have considerable advantages in extracting phenolic compounds and xanthones from G. cowa stem bark, resulting in enhanced antioxidant properties.This highlights the potential of NaDES as eco-friendly and effective solvents for the extraction of bioactive compounds from plant materials.
- 11 February 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (4) , 103695
Development of transethosomes patch for delivery atorvastatin calcium transdermally: In vitro and in vivo studies
- 11 February 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (4) , 103695
Development of transethosomes patch for delivery atorvastatin calcium transdermally: In vitro and in vivo studies
- Open Access
- 1 January 2025
- Published by Open Science Publishers LLP in Journal of Applied Pharmaceutical Science
- Vol. 16 (2) , 103-111
Bioanalytical method development and validation for the pharmacokinetics and biodistribution study of pirfenidone-loaded solid lipid nanoparticles
Pirfenidone (PRF) is a synthetic compound used to treat idiopathic pulmonary fibrosis, but its oral administration may cause systemic side effects. This study aimed to develop and validate a bioanalytical method to quantify PRF and evaluate the pharmacokinetic and biodistribution profile of PRF-loaded solid lipid nanoparticles (SLNs) delivered via the pulmonary route. A high-performance liquid chromatography (HPLC) method was validated following the Food and Drug Administration (FDA) guidelines, showing acceptable selectivity, accuracy, precision, and stability in plasma and lung tissue. PRF SLNs were prepared by solvent injection and had a mean particle size of 240.3 ± 3.57 nm and a polydispersity index of 0.386–0.392. Intratracheal administration of PRF SLNs resulted in higher maximum concentration and Area Under the Curve (AUC) values than oral PRF. Biodistribution studies showed that PRF SLNs achieved approximately fivefold greater AUC in lung tissue than free PRF, with lower distribution in the liver and kidneys. These findings indicate that pulmonary PRF SLNs enhance lung targeting and may reduce systemic exposure, while the validated HPLC method supports reliable pharmacokinetic and tissue distribution analysis.
- 1 January 2025
- Published by Open Science Publishers LLP in Journal of Applied Pharmaceutical Science
- Vol. 16 (2) , 103-111
Open AccessBioanalytical method development and validation for the pharmacokinetics and biodistribution study of pirfenidone-loaded solid lipid nanoparticles
Pirfenidone (PRF) is a synthetic compound used to treat idiopathic pulmonary fibrosis, but its oral administration may cause systemic side effects. This study aimed to develop and validate a bioanalytical method to quantify PRF and evaluate the pharmacokinetic and biodistribution profile of PRF-loaded solid lipid nanoparticles (SLNs) delivered via the pulmonary route. A high-performance liquid chromatography (HPLC) method was validated following the Food and Drug Administration (FDA) guidelines, showing acceptable selectivity, accuracy, precision, and stability in plasma and lung tissue. PRF SLNs were prepared by solvent injection and had a mean particle size of 240.3 ± 3.57 nm and a polydispersity index of 0.386–0.392. Intratracheal administration of PRF SLNs resulted in higher maximum concentration and Area Under the Curve (AUC) values than oral PRF. Biodistribution studies showed that PRF SLNs achieved approximately fivefold greater AUC in lung tissue than free PRF, with lower distribution in the liver and kidneys. These findings indicate that pulmonary PRF SLNs enhance lung targeting and may reduce systemic exposure, while the validated HPLC method supports reliable pharmacokinetic and tissue distribution analysis.
- Open Access
- 1 December 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (12) , 2073-2084
Enhanced Bioavailability and Bone Health: Transdermal Delivery of Calcitonin Transfersomes Gel Reduces Osteoclast Numbers and Increases Bone Calcium in Ovariectomized Rats
Salmon calcitonin (sCT) is a peptide hormone primarily used for osteoporosis due to the ability to regulate calcium and bone metabolism. However, its therapeutic efficacy through conventional routes of administration such as injection is limited by poor bioavailability, rapid degradation, and its invasive nature. Transdermal delivery systems, such as transfersome gels, offer a promising alternative by enhancing absorption through the skin. Therefore, this study aimed to evaluate the relative bioavailability and pharmacodynamic effects of transdermally administered sCT transfersomes gel in female rats. Pharmacokinetic tests of the transfersomes gel containing sCT were conducted on female Sprague-Dawley rats. A total of 10 rats were divided into 2 groups (n = 5 each) and received a single dose of sCT (4 µg/200 g). Group 1 was treated with transdermally administered transfersomes gel, and Group 2 received subcutaneously administered injection solution. As sCT concentration versus time was calculated, area under the curve (AUC) was determined. The pharmacodynamic analysis was conducted by counting the number of osteoclasts using TRAP staining and analyzing calcium levels in rats’ tibia bone using Atomic Absorption Spectroscopy (AAS). In the pharmacokinetic test of transdermally administered sCT transfersomes gel, there was an increase in relative bioavailability by 144.32% compared to the subcutaneously administered injection solution. The results of pharmacodynamic analysis showed that sCT transfersomes gel increased calcium levels in rat tibia bone and reduced the number of osteoclasts in ovariectomized (Ovx) samples. This showed that sCT transfersomes gel could improve the relative bioavailability and prevent osteoporosis in Ovx rats.
- 1 December 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (12) , 2073-2084
Open AccessEnhanced Bioavailability and Bone Health: Transdermal Delivery of Calcitonin Transfersomes Gel Reduces Osteoclast Numbers and Increases Bone Calcium in Ovariectomized Rats
Salmon calcitonin (sCT) is a peptide hormone primarily used for osteoporosis due to the ability to regulate calcium and bone metabolism. However, its therapeutic efficacy through conventional routes of administration such as injection is limited by poor bioavailability, rapid degradation, and its invasive nature. Transdermal delivery systems, such as transfersome gels, offer a promising alternative by enhancing absorption through the skin. Therefore, this study aimed to evaluate the relative bioavailability and pharmacodynamic effects of transdermally administered sCT transfersomes gel in female rats. Pharmacokinetic tests of the transfersomes gel containing sCT were conducted on female Sprague-Dawley rats. A total of 10 rats were divided into 2 groups (n = 5 each) and received a single dose of sCT (4 µg/200 g). Group 1 was treated with transdermally administered transfersomes gel, and Group 2 received subcutaneously administered injection solution. As sCT concentration versus time was calculated, area under the curve (AUC) was determined. The pharmacodynamic analysis was conducted by counting the number of osteoclasts using TRAP staining and analyzing calcium levels in rats’ tibia bone using Atomic Absorption Spectroscopy (AAS). In the pharmacokinetic test of transdermally administered sCT transfersomes gel, there was an increase in relative bioavailability by 144.32% compared to the subcutaneously administered injection solution. The results of pharmacodynamic analysis showed that sCT transfersomes gel increased calcium levels in rat tibia bone and reduced the number of osteoclasts in ovariectomized (Ovx) samples. This showed that sCT transfersomes gel could improve the relative bioavailability and prevent osteoporosis in Ovx rats.
- Open Access
- 25 September 2024
- Published by Universitas Gadjah Mada in Indonesian Journal of Pharmacy
- p. 501–511
Optimizing the Formula of Polymeric-Based Aripiprazole Nanosuspension Using Response Surface Methodology for Intranasal Drug Delivery
This study aimed to optimize the formula of aripiprazole nanosuspension for intranasal drug delivery. Response Surface Methodology (RSM) was employed to determine the influence of independent variables, including drug concentration, polymer concentration, and the ratio of polymer combination, on the nanosuspension characteristics. The parameters under investigation were particle size (d mean), polydispersity index, and drug content. Fifteen formulas were prepared using the high-shear homogenization–ultrasonication method, and the Design Expert software was applied for optimum formula determination. The result showed significant effects of the independent variables on the nanosuspension characteristics, with particle sizes ranging from 143.6 – 334.6 nm, PDI values of 0.302 – 0.649, and drug content was 98.7 – 102.1 %. The predicted optimum formula had a drug concentration of 28 mg/mL in the organic solvent, polymer concentration of 1.5% (w/v), and HPMC to PVP ratio of 1.4 with desirability of 0.94. Additionally, it exhibited desirable characteristics, such as a particle size of 171.2 11.4 nm, a PDI value of 0.317 0.02, and a high drug content of 100.04 0.65%. In conclusion, the presented methodology appeared to be perfect for the optimization of the aripiprazole nanosuspension formula to ensure suitability for nose-to-brain drug delivery.
- 25 September 2024
- Published by Universitas Gadjah Mada in Indonesian Journal of Pharmacy
- p. 501–511
Open AccessOptimizing the Formula of Polymeric-Based Aripiprazole Nanosuspension Using Response Surface Methodology for Intranasal Drug Delivery
This study aimed to optimize the formula of aripiprazole nanosuspension for intranasal drug delivery. Response Surface Methodology (RSM) was employed to determine the influence of independent variables, including drug concentration, polymer concentration, and the ratio of polymer combination, on the nanosuspension characteristics. The parameters under investigation were particle size (d mean), polydispersity index, and drug content. Fifteen formulas were prepared using the high-shear homogenization–ultrasonication method, and the Design Expert software was applied for optimum formula determination. The result showed significant effects of the independent variables on the nanosuspension characteristics, with particle sizes ranging from 143.6 – 334.6 nm, PDI values of 0.302 – 0.649, and drug content was 98.7 – 102.1 %. The predicted optimum formula had a drug concentration of 28 mg/mL in the organic solvent, polymer concentration of 1.5% (w/v), and HPMC to PVP ratio of 1.4 with desirability of 0.94. Additionally, it exhibited desirable characteristics, such as a particle size of 171.2 11.4 nm, a PDI value of 0.317 0.02, and a high drug content of 100.04 0.65%. In conclusion, the presented methodology appeared to be perfect for the optimization of the aripiprazole nanosuspension formula to ensure suitability for nose-to-brain drug delivery.
- Open Access
- 25 August 2024
- Published by Universitas Indonesia in Pharmaceutical Sciences and Research
- Vol. 11 (2) , 2
Harnessing the Potential of Several Local Indonesian Tuber-derived Starches as Pharmaceutical Excipients
Starch is one of the widely required excipients in pharmaceutical dosage forms manufacturing. Indonesia’s rich biodiversity, encompassing tubers like arrowroot, taro beneng, porang, ganyong and yams, harbours the potential for novel starch excipient sources. These tubers provide starch variations with distinct functional properties influenced by the natural starch granules’ properties and amylose-amylopectin ratio. Previous research utilizing natural and modified starches from these tubers has demonstrated their potential in pharmaceutical formulation. These starch tubers have been studied and provided promising results in tablet formulation and film development. Additionally, they could be involved in developing more advanced dosage forms, such as starch nanoparticles and nanocrystals. The rich versatility of these tuber starches solidified a promising future for their development, offering significant advantages for both pharmaceutical technology and economic value perspectives. Optimization of the starch yield, mainly through extraction, is crucial to fully realizing the economic prospect of tuber-derived starches.
- 25 August 2024
- Published by Universitas Indonesia in Pharmaceutical Sciences and Research
- Vol. 11 (2) , 2
Open AccessHarnessing the Potential of Several Local Indonesian Tuber-derived Starches as Pharmaceutical Excipients
Starch is one of the widely required excipients in pharmaceutical dosage forms manufacturing. Indonesia’s rich biodiversity, encompassing tubers like arrowroot, taro beneng, porang, ganyong and yams, harbours the potential for novel starch excipient sources. These tubers provide starch variations with distinct functional properties influenced by the natural starch granules’ properties and amylose-amylopectin ratio. Previous research utilizing natural and modified starches from these tubers has demonstrated their potential in pharmaceutical formulation. These starch tubers have been studied and provided promising results in tablet formulation and film development. Additionally, they could be involved in developing more advanced dosage forms, such as starch nanoparticles and nanocrystals. The rich versatility of these tuber starches solidified a promising future for their development, offering significant advantages for both pharmaceutical technology and economic value perspectives. Optimization of the starch yield, mainly through extraction, is crucial to fully realizing the economic prospect of tuber-derived starches.
- Open Access
- 7 July 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 283-290
RESPONSE SURFACE METHODOLOGY-AIDED DEVELOPMENT OF PIRFENIDONE-LOADED SOLID LIPID NANOPARTICLES FOR INTRAPULMONARY DRUG DELIVERY SYSTEM
Objective: This study aims to determine the optimized Pirfenidone-loaded Solid Lipid Nanoparticles (P-SLN) formula for Intrapulmonary Drug Delivery System (IPDDS) using Response Surface Methodology (RSM). Methods: Box-Behnken design was applied to create fifteen P-SLN formulas comprising three independent variables, namely lipid-to-drug ratio, polymer type, and polymer concentration, and three dependent variables, including particle size, Polydispersity Index (PDI), and entrapment efficiency. The P-SLNs were prepared by solvent injection followed by the ultrasonication method. Those formulas were optimized with the RSM approach using the Design Expert®. Then, the optimized P-SLN was further characterized for morphology, moisture content, aerodynamic performance, and dissolution profile. Results: The optimization process, assisted by RSM, determined that the optimized P-SLN had a lipid-to-drug ratio of 6:1 and contained 0.5% Plasdone K-29/32. The resulting P-SLN had a spherical shape with a particle size of 212.7 nm, a PDI of 0.39, an entrapment efficiency of 95.02%, and a low moisture content of 1.59%. The optimized P-SLN also exhibited appropriate IPDDS required characteristics, including a Mass Median Aerodynamic Diameter (MMAD) ranging from 0.540–12.122 μm and a Respirable Fraction (RF) of 12.4%. Moreover, the release of pirfenidone from this optimized formula was 89.61% and 69.28% in pH 4.5 and 7.4 buffer media, respectively, in 45 min through a combination of diffusion and polymer swelling mechanisms. Conclusion: The optimized P-SLN showed promising potential as an IPDDS for pirfenidone.
- 7 July 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 283-290
Open AccessRESPONSE SURFACE METHODOLOGY-AIDED DEVELOPMENT OF PIRFENIDONE-LOADED SOLID LIPID NANOPARTICLES FOR INTRAPULMONARY DRUG DELIVERY SYSTEM
Objective: This study aims to determine the optimized Pirfenidone-loaded Solid Lipid Nanoparticles (P-SLN) formula for Intrapulmonary Drug Delivery System (IPDDS) using Response Surface Methodology (RSM). Methods: Box-Behnken design was applied to create fifteen P-SLN formulas comprising three independent variables, namely lipid-to-drug ratio, polymer type, and polymer concentration, and three dependent variables, including particle size, Polydispersity Index (PDI), and entrapment efficiency. The P-SLNs were prepared by solvent injection followed by the ultrasonication method. Those formulas were optimized with the RSM approach using the Design Expert®. Then, the optimized P-SLN was further characterized for morphology, moisture content, aerodynamic performance, and dissolution profile. Results: The optimization process, assisted by RSM, determined that the optimized P-SLN had a lipid-to-drug ratio of 6:1 and contained 0.5% Plasdone K-29/32. The resulting P-SLN had a spherical shape with a particle size of 212.7 nm, a PDI of 0.39, an entrapment efficiency of 95.02%, and a low moisture content of 1.59%. The optimized P-SLN also exhibited appropriate IPDDS required characteristics, including a Mass Median Aerodynamic Diameter (MMAD) ranging from 0.540–12.122 μm and a Respirable Fraction (RF) of 12.4%. Moreover, the release of pirfenidone from this optimized formula was 89.61% and 69.28% in pH 4.5 and 7.4 buffer media, respectively, in 45 min through a combination of diffusion and polymer swelling mechanisms. Conclusion: The optimized P-SLN showed promising potential as an IPDDS for pirfenidone.
- Open Access
- 1 July 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (7) , 969-982
An Investigation of Atorvastatin Calcium Loaded Transethosomes for Transdermal Delivery and Validation of HPLC Methods
Atorvastatin calcium is an antihyperlipidemic agent with low bioavailability due to the first-pass metabolism after oral administration. To overcome the limitation, an alternative method for delivering drug molecules to the systemic circulation is needed, such as transethosomes produced for transdermal delivery. Therefore, this study aimed to produce atorvastatin calcium transethosomes with characteristics suitable for transdermal delivery using validated analytical method. Transethosomes formulations were prepared with different concentrations of soy lecithin and ethanol. All formulations were evaluated for particle size, zeta potential, polydispersity index (PDI), drug content, and deformability index. Validation of the analytical method of atorvastatin calcium was carried out using system suitability, selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy, and robustness. The result showed that transethosomes had a small particle size of 123.90 nm-165.10 nm, high zeta potential values, acceptable PDI, the highest atorvastatin calcium content, and good deformability index. In addition, the system suitability test results were acceptable and there was no interference in the atorvastatin calcium area. Linearity showed r =0.9999 with LOD and LOQ values of 0.388 µg/mL and 1.176 µg/mL, respectively. The % RSD in the precision was < 2 and the recovery in the accuracy was 98.76%-101.04%. The method proved to be robust with respect to mobile phase pH changes. Based on the results, atorvastatin calcium-loaded transethosomes were suitable for transdermal delivery and could be effectively produced with a 3% soy lecithin and 30% ethanol concentration. The analytical method for determining drug content of atorvastatin calcium-loaded transethosomes could be effectively applied.
- 1 July 2024
- Published by International Society of Communication and Development Between Universities (ISCDBU) in Journal of Medicinal and Chemical Sciences
- Vol. 7 (7) , 969-982
Open AccessAn Investigation of Atorvastatin Calcium Loaded Transethosomes for Transdermal Delivery and Validation of HPLC Methods
Atorvastatin calcium is an antihyperlipidemic agent with low bioavailability due to the first-pass metabolism after oral administration. To overcome the limitation, an alternative method for delivering drug molecules to the systemic circulation is needed, such as transethosomes produced for transdermal delivery. Therefore, this study aimed to produce atorvastatin calcium transethosomes with characteristics suitable for transdermal delivery using validated analytical method. Transethosomes formulations were prepared with different concentrations of soy lecithin and ethanol. All formulations were evaluated for particle size, zeta potential, polydispersity index (PDI), drug content, and deformability index. Validation of the analytical method of atorvastatin calcium was carried out using system suitability, selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy, and robustness. The result showed that transethosomes had a small particle size of 123.90 nm-165.10 nm, high zeta potential values, acceptable PDI, the highest atorvastatin calcium content, and good deformability index. In addition, the system suitability test results were acceptable and there was no interference in the atorvastatin calcium area. Linearity showed r =0.9999 with LOD and LOQ values of 0.388 µg/mL and 1.176 µg/mL, respectively. The % RSD in the precision was < 2 and the recovery in the accuracy was 98.76%-101.04%. The method proved to be robust with respect to mobile phase pH changes. Based on the results, atorvastatin calcium-loaded transethosomes were suitable for transdermal delivery and could be effectively produced with a 3% soy lecithin and 30% ethanol concentration. The analytical method for determining drug content of atorvastatin calcium-loaded transethosomes could be effectively applied.
- Open Access
Promising brain biodistribution of insulin via intranasal dry powder for nose-to-brain delivery